

All registrations, both new participants and those being re-registered count towards UK CRN accrual data. **UK CRN ID: 7302**

CRITERIA FOR REGISTRATION

Diagnosis of
Rheumatoid
Arthritis

Age 16 years
and over

Starting treatment with
biologic, biosimilar or
other advanced
targeted therapy.

- **Patients who are new to the study:** registration documents must be received at the study offices within 6 months of therapy start date.
- **Patients already registered and starting a new eligible therapy:** re-registration paperwork should be received at the study offices as soon as possible, but within 24 months of the switch at the very latest.

Currently accepting registrations for:

HUMIRA (adalimumab)*

ENBREL (etanercept)*

REMICADE (infliximab)*

AMGEVITA (adalimumab)

HULIO (adalimumab)

HYRIMOZ (adalimumab)

IMRALDI (adalimumab)

OLUMIANT (baricitinib)

CIMZIA (certolizumab)

ERELZI (etanercept)

BENEPALI (etanercept)

INFLECTRA (infliximab)

REMSIMA (infliximab)

FLIXABI (infliximab)

RIXATHON (rituximab)

KEVZARA (sarilumab)

ROACTEMRA (tocilizumab)

XELJANZ (tofacitinib)

***Humira, Enbrel & Remicade participants must be biologic, biosimilar & targeted therapy naïve.**

Registrations for all other therapies do not have this requirement.

Registration details and printable documents are available at www.bsrbr.org

Have a question? Please contact us! Tel: 0161 275 1652/ 7390

biologics.register@manchester.ac.uk